Nifty
Sensex
:
:
16992.55
57720.37
47.50 (0.28%)
193.27 (0.34%)

Pharmaceuticals & Drugs - Global

Rating :
55/99

BSE: 500087 | NSE: CIPLA

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 70,787.11
  • 26.83
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 69,682.77
  • 0.57%
  • 3.12

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.61%
  • 0.53%
  • 14.72%
  • FII
  • DII
  • Others
  • 28.38%
  • 19.15%
  • 3.61%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.15
  • 7.51
  • 8.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.46
  • 12.96
  • 7.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.01
  • 12.35
  • 16.64

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 32.96
  • 31.35
  • 31.88

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.60
  • 3.43
  • 3.79

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.71
  • 15.33
  • 16.37

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Net Sales
5,810.09
5,478.86
6.05%
5,828.54
5,519.80
5.59%
5,375.19
5,504.35
-2.35%
5,260.33
4,606.45
14.19%
Expenses
4,402.54
4,247.89
3.64%
4,526.21
4,293.60
5.42%
4,231.84
4,158.46
1.76%
4,510.61
3,810.21
18.38%
EBITDA
1,407.55
1,230.97
14.34%
1,302.33
1,226.20
6.21%
1,143.35
1,345.89
-15.05%
749.72
796.24
-5.84%
EBIDTM
24.23%
22.47%
22.34%
22.21%
21.27%
24.45%
14.25%
17.29%
Other Income
114.44
91.29
25.36%
122.95
60.67
102.65%
103.43
64.93
59.29%
64.02
60.13
6.47%
Interest
31.82
20.68
53.87%
25.55
38.00
-32.76%
17.81
29.57
-39.77%
18.10
27.45
-34.06%
Depreciation
272.11
247.47
9.96%
299.37
253.06
18.30%
254.41
261.11
-2.57%
290.31
285.19
1.80%
PBT
1,218.06
1,054.11
15.55%
1,100.36
995.81
10.50%
974.56
995.52
-2.11%
447.83
543.73
-17.64%
Tax
410.01
295.16
38.91%
302.60
283.81
6.62%
268.00
283.72
-5.54%
71.11
128.22
-44.54%
PAT
808.05
758.95
6.47%
797.76
712.00
12.04%
706.56
711.80
-0.74%
376.72
415.51
-9.34%
PATM
13.91%
13.85%
13.69%
12.90%
13.14%
12.93%
7.16%
9.02%
EPS
9.92
9.03
9.86%
9.78
8.82
10.88%
8.51
8.86
-3.95%
4.49
5.13
-12.48%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
22,274.15
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
Net Sales Growth
5.52%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
 
Cost Of Goods Sold
8,335.61
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
Gross Profit
13,938.54
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
GP Margin
62.58%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
Total Expenditure
17,671.20
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
Power & Fuel Cost
-
331.03
308.26
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
% Of Sales
-
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
Employee Cost
-
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
% Of Sales
-
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
Manufacturing Exp.
-
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
541.58
% Of Sales
-
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
6.54%
General & Admin Exp.
-
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
% Of Sales
-
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
Selling & Distn. Exp.
-
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
% Of Sales
-
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
Miscellaneous Exp.
-
565.55
508.00
692.12
855.40
968.98
645.54
657.29
497.67
441.10
466.22
% Of Sales
-
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
4.29%
EBITDA
4,602.95
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
EBITDA Margin
20.66%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
Other Income
404.84
321.73
269.77
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
Interest
93.28
106.35
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
Depreciation
1,116.20
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
PBT
3,740.81
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
Tax
1,051.72
933.80
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
Tax Rate
28.11%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
PAT
2,689.09
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
PAT before Minority Interest
2,645.34
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
Minority Interest
-43.75
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
PAT Margin
12.07%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
PAT Growth
3.50%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
 
EPS
33.52
31.53
30.14
19.87
19.26
17.62
12.63
17.10
15.03
17.46
19.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
Share Capital
161.36
161.29
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
Total Reserves
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
Non-Current Liabilities
621.70
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
Secured Loans
376.20
355.32
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
Unsecured Loans
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
Long Term Provisions
100.22
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
Current Liabilities
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
Trade Payables
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
Other Current Liabilities
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
Short Term Borrowings
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
Short Term Provisions
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
Total Liabilities
26,651.95
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
Net Block
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
Gross Block
16,975.58
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
Accumulated Depreciation
7,318.07
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
Non Current Assets
11,924.75
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
Capital Work in Progress
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
Non Current Investment
355.63
545.43
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
Long Term Loans & Adv.
695.49
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
971.75
Other Non Current Assets
424.12
102.51
77.61
166.82
255.71
210.06
176.54
168.88
158.89
162.09
Current Assets
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
Current Investments
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
Inventories
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
Sundry Debtors
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
Cash & Bank
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
Other Current Assets
1,812.70
347.54
442.02
415.53
1,599.13
1,226.01
1,223.17
858.67
630.63
468.31
Short Term Loans & Adv.
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
463.21
Net Current Assets
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
Total Assets
26,635.58
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
PBT
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
Adjustment
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
Changes in Working Capital
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
Cash after chg. in Working capital
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
Net Fixed Assets
779.77
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
Net Investments
-1,124.06
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
Others
-1,527.59
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
196.30
Cash from Financing Activity
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
Net Cash Inflow / Outflow
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
Opening Cash & Equivalents
790.43
649.13
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
Closing Cash & Equivalent
658.11
790.43
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
257.78
226.73
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
ROA
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
ROE
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
ROCE
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
Fixed Asset Turnover
1.82
1.85
1.89
1.79
1.25
1.36
1.40
1.26
1.47
1.69
Receivable days
42.19
47.44
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
Inventory Days
61.53
58.49
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
Payable days
98.28
107.95
128.84
59.02
57.37
46.96
51.51
52.17
44.93
48.58
Cash Conversion Cycle
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
112.14
107.41
113.72
Total Debt/Equity
0.04
0.10
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
Interest Cover
33.85
21.47
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79

News Update:


  • Cipla to sell 51.18% stake in Cipla Quality Chemical Industries
    15th Mar 2023, 09:25 AM

    The proposed sale is expected to be completed by May 31, 2023

    Read More
  • Cipla gets 8 inspectional observations from USFDA for Pithampur facility
    20th Feb 2023, 09:58 AM

    USFDA has conducted a cGMP inspection at Cipla’s Pithampur manufacturing facility

    Read More
  • Cipla reports 7% rise in Q3 consolidated net profit
    25th Jan 2023, 16:21 PM

    Total consolidated income of the company increased 6.36% at Rs 5,924.53 crore for Q3FY23

    Read More
  • Cipla - Quarterly Results
    25th Jan 2023, 14:10 PM

    Read More
  • Cipla launches Cippoint for non-communicable diseases, infectious disease
    18th Jan 2023, 10:42 AM

    Cippoint aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience

    Read More
  • Cipla’s arm signs definitive agreements for equity investment in Ethris GmbH
    30th Dec 2022, 09:41 AM

    A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris’ innovative portfolio in Cipla’s key emerging markets

    Read More
  • Cipla eyeing higher capital expenditure on automation for three more years
    28th Dec 2022, 18:15 PM

    The company has started its investment journey on the automation front two years ago and has already been recognised for its work by multiple bodies

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.